Your session is about to expire
← Back to Search
Other
[14C]-DZD9008 for Healthy Subjects
Phase 1
Waitlist Available
Led By Blanchard
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 85 days
Awards & highlights
Study Summary
This is a phase 1, open-label, ADME study with single oral administration of [14C]-DZD9008 in healthy subjects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 85 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 85 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Amount of Total Radioactivity Excreted in Feces (Ae [Fe])
Amount of Total Radioactivity Excreted in Urine (Ae [UR])
Percentage of Administered Radioactive Dose (%Dose) Excreted in Feces for [14C]-DZD9008
+3 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: [14C]-DZD9008Experimental Treatment1 Intervention
A Single dose of [14C]-DZD9008
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[14C]-DZD9008
2021
Completed Phase 1
~10
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Dizal PharmaceuticalsLead Sponsor
20 Previous Clinical Trials
2,041 Total Patients Enrolled
BlanchardPrincipal InvestigatorCovance
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger